Historique
Article de Périodique
Introduction of the EuropASI in Norway: clinical and research experiences from a cost-effectiveness study (2004)
(Introduction de l'ASI européen en Norvège : résultats d'une étude sur le rapport coût-bénéfice au niveau de la clinique et de la recherche)
Auteur(s) :
G. LAURITZEN ;
E. RAVNDAL
Article en page(s) :
141-146
Refs biblio. :
21
Domaine :
Plusieurs produits / Several products
Langue(s) :
Anglais
Thésaurus mots-clés
ASI
;
COUT
;
EVALUATION
;
RECHERCHE
;
TRAITEMENT
;
ENQUETE
;
SUBSTITUTION
Thésaurus géographique
NORVEGE
Note générale :
Journal of Substance Use, 2004, 9, (3-4), 141-146
Résumé :
ENGLISH :
Diverse approaches to treatment research in Norway have hampered comparative studies. The European Addiction Severity Index (EuropASI) was chosen as the main instrument in the first comprehensive study of drug abusers undergoing treatment. The study comprises 482 drug abusers in 20 different treatment programmes who were interviewed at intake to inpatient modalities, substitution programmes and outpatient clinics. They were interviewed twice again at 1-year intervals with a follow-up rate of 90%. The clients' response to the EuropASI was positive, and it has been found to be beneficial as an instrument for clinical use and for research purposes. This paper focuses on the broad interest in the EuropASI in the Norwegian drug and alcohol treatment field and recommends some changes that would improve its construct validity and bolster its reliability. (Review' s abstract)
ENGLISH :
Diverse approaches to treatment research in Norway have hampered comparative studies. The European Addiction Severity Index (EuropASI) was chosen as the main instrument in the first comprehensive study of drug abusers undergoing treatment. The study comprises 482 drug abusers in 20 different treatment programmes who were interviewed at intake to inpatient modalities, substitution programmes and outpatient clinics. They were interviewed twice again at 1-year intervals with a follow-up rate of 90%. The clients' response to the EuropASI was positive, and it has been found to be beneficial as an instrument for clinical use and for research purposes. This paper focuses on the broad interest in the EuropASI in the Norwegian drug and alcohol treatment field and recommends some changes that would improve its construct validity and bolster its reliability. (Review' s abstract)
Affiliation :
Norwegian Institute for Alcohol and Drug Research (SIRUS), Box 565 Sentrum, N-0105 Oslo
Norvège. Norway.
Norvège. Norway.